Literature DB >> 26849997

Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.

P Strajhar1, Y Schmid2, E Liakoni2, P C Dolder2,3, K M Rentsch3, D V Kratschmar1, A Odermatt1, M E Liechti2.   

Abstract

Lysergic acid diethylamide (LSD) is a serotonin 5-hydroxytryptamine-2A (5-HT2A ) receptor agonist that is used recreationally worldwide. Interest in LSD research in humans waned after the 1970s, although the use of LSD in psychiatric research and practice has recently gained increasing attention. LSD produces pronounced acute psychedelic effects, although its influence on plasma steroid levels over time has not yet been characterised in humans. The effects of LSD (200 μg) or placebo on plasma steroid levels were investigated in 16 healthy subjects using a randomised, double-blind, placebo-controlled, cross-over study design. Plasma concentration-time profiles were determined for 15 steroids using liquid-chromatography tandem mass-spectrometry. LSD increased plasma concentrations of the glucocorticoids cortisol, cortisone, corticosterone and 11-dehydrocorticosterone compared to placebo. The mean maximum concentration of LSD was reached at 1.7 h. Mean peak psychedelic effects were reached at 2.4 h, with significant alterations in mental state from 0.5 h to > 10 h. Mean maximal concentrations of cortisol and corticosterone were reached at 2.5 h and 1.9 h, and significant elevations were observed 1.5-6 h and 1-3 h after drug administration, respectively. LSD also significantly increased plasma concentrations of the androgen dehydroepiandrosterone but not other androgens, progestogens or mineralocorticoids compared to placebo. A close relationship was found between plasma LSD concentrations and changes in plasma cortisol and corticosterone and the psychotropic response to LSD, and no clockwise hysteresis was observed. In conclusion, LSD produces significant acute effects on circulating steroids, especially glucocorticoids. LSD-induced changes in circulating glucocorticoids were associated with plasma LSD concentrations over time and showed no acute pharmacological tolerance.
© 2016 British Society for Neuroendocrinology.

Entities:  

Keywords:  glucocorticoid; lysergic acid diethylamide; serotonin; steroid

Mesh:

Substances:

Year:  2016        PMID: 26849997     DOI: 10.1111/jne.12374

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  24 in total

1.  Research ethics aspects of experimentation with LSD on human subjects: a historical and ethical review.

Authors:  Kristóf János Bodnár; Péter Kakuk
Journal:  Med Health Care Philos       Date:  2019-06

2.  Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.

Authors:  Patrick C Dolder; Matthias E Liechti; Katharina M Rentsch
Journal:  J Clin Lab Anal       Date:  2017-05-26       Impact factor: 2.352

3.  Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity.

Authors:  Wan-Hui Liao; Claudia Suendermann; Andrea Eva Steuer; Gustavo Pacheco Lopez; Alex Odermatt; Nourdine Faresse; Maciej Henneberg; Wolfgang Langhans
Journal:  JCI Insight       Date:  2018-07-26

4.  LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality.

Authors:  Patrick C Dolder; Yasmin Schmid; Felix Müller; Stefan Borgwardt; Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2016-06-01       Impact factor: 7.853

5.  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.

Authors:  Patrick C Dolder; Yasmin Schmid; Andrea E Steuer; Thomas Kraemer; Katharina M Rentsch; Felix Hammann; Matthias E Liechti
Journal:  Clin Pharmacokinet       Date:  2017-10       Impact factor: 6.447

6.  Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.

Authors:  Patrick C Dolder; Felix Müller; Yasmin Schmid; Stefan J Borgwardt; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2017-05-27       Impact factor: 4.530

7.  Alterations of consciousness and mystical-type experiences after acute LSD in humans.

Authors:  Matthias E Liechti; Patrick C Dolder; Yasmin Schmid
Journal:  Psychopharmacology (Berl)       Date:  2016-10-07       Impact factor: 4.530

8.  A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects.

Authors:  Patrick C Dolder; Edna Grünblatt; Felix Müller; Stefan J Borgwardt; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

9.  Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects.

Authors:  F Mueller; C Lenz; P C Dolder; S Harder; Y Schmid; U E Lang; M E Liechti; S Borgwardt
Journal:  Transl Psychiatry       Date:  2017-04-04       Impact factor: 6.222

10.  Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin.

Authors:  Friederike Holze; Isidora Avedisian; Nimmy Varghese; Anne Eckert; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2021-07-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.